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The availability of longstanding collection of detailed cancer patient information
makes multivariable modelling of cancer‐specific hazard of death appealing. We
propose to report variation in survival explained by each variable that consti-
tutes these models. We adapted the ranks explained (RE) measure to the relative
survival data setting, ie, when competing risks of death are accounted for
through life tables from the general population. RE is calculated at each event
time. We introduce weights for each death reflecting its probability to be a can-
cer death. RE varies between −1 and +1 and can be reported at given times in
the follow‐up and as a time‐varying measure from diagnosis onward.We present
an application for patients diagnosed with colon or lung cancer in England. The
RE measure shows reasonable properties and is comparable in both relative and
cause‐specific settings. One year after diagnosis, RE for the most complex excess
hazard models reaches 0.56, 95% CI: 0.54 to 0.58 (0.58 95% CI: 0.56–0.60) and
0.69, 95% CI: 0.68 to 0.70 (0.67, 95% CI: 0.66–0.69) for lung and colon cancer
men (women), respectively. Stage at diagnosis accounts for 12.4% (10.8%) of
the overall variation in survival among lung cancer patients whereas it carries
61.8% (53.5%) of the survival variation in colon cancer patients. Variables other
than performance status for lung cancer (10%) contribute very little to the over-
all explained variation. The proportion of the variation in survival explained by
key prognostic factors is a crucial information toward understanding the mech-
anisms underpinning cancer survival. The time‐varying RE provides insights
into patterns of influence for strong predictors.
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1 | INTRODUCTION
Complex, multivariable modelling of time‐to‐event data is easily accessible through user‐friendly specific commands in
common statistical software.1-4 In such models, the effects of prognostic factors on hazard of death are modelled and
estimated. Possible non‐linearity and time dependence of their effects can be incorporated. The model gives the usual
estimates of effect and P‐values, but often the estimation of survival for the cohort is the metric of choice.
Datasets in population‐based research contain information on virtually all patients in a given area or country for a
given period of time: it can represent such large numbers that statistical significance does not bring much information
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the
original work is properly cited.
© 2018 The Authors. Statistics in Medicine published by John Wiley & Sons Ltd.
Received: 21 June 2017 Revised: 30 January 2018 Accepted: 31 January 2018
DOI: 10.1002/sim.7645
Statistics in Medicine. 2018;1–17. wileyonlinelibrary.com/journal/sim 1
on the relative importance of prognostic factors. A measure of explained variation does not aim at providing information
on how well a model fits the data at hand but provides information on how much of the variation in survival between
records is explained by the model, and hence by the prognostic factors that compose the model.
Although survival models do not carry good prediction properties, there is a number of measures proposed for evalu-
ating their prognostic characteristics5 by ways of measures of prediction accuracy,6 discrimination potential,7 and the pro-
portion of variation explained.8 Most measures have been designed in the context of the Cox model,9 widely used in
traditional survival analyses or clinical trials. However, when focussing on survival from a disease, eg, cancer, survival
analysis needs to account for competing risks of death. In the population‐based cancer survival context, the exact cause
of death of patients is unknown or considered unreliable. In this context, we rely on the relative survival data setting,
in which the hazard of death from the cancer, or excess hazard, is estimated by comparing the overall mortality of the can-
cer patients to their expected mortality provided by life tables built for the general population from which the cancer
patients come.10 The effects of explanatory variables on the excess hazard can be modelled using various excess hazard
models.3,11 Net survival, the survival of the cohort of cancer patients, cancer being the only cause of death, can be derived
from suchmodels, providing these are well specified. The assumption of informative censoring is replaced by amore plau-
sible assumption of independence of the forces of mortality, providing the effects of the variables stratifying the life tables,
such as sex, age, region, deprivation, and ethnicity, are adjusted for in the model.12
In this paper, we adapt a measure of explained variation, ranks explained (RE),13 to the context of excess hazard
models in the relative survival data setting. We address challenges related to the specificities of that setting and the excess
hazard modelling, while the interpretation of the adapted RE is kept as simple as with the original RE measure. This is
exemplified by an extensive illustration using population‐based cancer registry data on patients diagnosed with colon or
lung cancer in England.
The next section summarises the characteristics of the measure of explained variation, RE, then presents the excess
hazard models and how RE was adapted to the relative survival data setting. In a third section, we describe the design of
our simulation‐based analyses aimed at exploring the features of RE. The following section presents an application based
on colon and lung cancer patients in England. The discussion wraps up the main advantages and limitations of the mea-
sure proposed.
2 | METHODS
2.1 | The RE measure in the overall survival setting
The RE measure, standing for “ranks explained”, was introduced by Stare et al.13 It aims at providing a measure of the
variation in the ranks observed in survival‐time data explained by a given model. It can be viewed as a generalisation of
the C‐index.14 It satisfies the following list of criteria:
(1) Applicability to multiple end‐point survival
(2) Facility to incorporate time‐varying and/or dynamic covariates and/or time‐dependent effects
(3) Model‐free interpretation on a well‐understood scale, to allow comparison between non‐nested models
(4) Applicability to both parametric and semiparametric models
(5) Consistency under general independent censoring mechanisms, including intermittent missingness and delayed
entry or truncation
Some of these points, particularly (2), (3), and (5), make the measure appealing to the excess hazard context.
Technically, the sum of the variation in ranks, explained by the model is compared with the sum of the total
variation in ranks there is to explain. The “unit” is the rank that each record is given at each failure time ti, ie,
the predicted position at which the record under observation will fail among all observations that have yet to fail
(observations in the risk set Ri). The total variation is viewed as the difference between the ranks allocated under
a “null model” (ri,null), and the ranks allocated under a “perfect model” (ri,perfect), ie, the record that fails is always
given rank 1:
ri;null ¼ k þ 1ð Þ2 ∀k ∈ Ri; i:e: tk > ti
ri;perfect ¼ 1:
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We define the “null model” as a model in which all records that have not yet failed are given the same mean rank: it
corresponds to a scenario in which one would lack information regarding the expected time to failure of the individuals
in the risk set, and all individuals would therefore have the same probability to fail next.
The variation that is explained by a proposed model is the difference between the ranks allocated under a “null
model” and the ranks that are allocated under the proposed model (ri,model).
ri;model ¼ 1þ∑k∈Ri lλk tið Þ>λi tið Þ
Where λk tið Þ and λi tið Þ are the hazards for patients k and i, respectively, at patient's i time of failure ti.
The final statistic sums these differences over all individual failure times so that the statistic is defined, in the case of
single‐event survival data by:
RE ¼ ∑i ri;null− ri;model
 
∑i ri;null− ri;perfect
  : (1)
Through censoring patients leave the cohort. In order for those who stay in the cohort to be representative of those
who left, we weight records that are more likely to have missing observed failure time. Typically, the weights are the
reverse Kaplan Meier estimates (
1
cGit ), in the case of survival data with right censoring.
5,15 The delta method is also used
to provide a formulation for the variance of RE. Full details can be found in Stare et al.13
RE ¼
∑i ∫
τ
0
1
cGit * ri;null tð Þ− ri;model tð Þ
 
dNi tð Þ
∑i ∫
τ
0
1
cGit * ri;null tð Þ− ri;perfect tð Þ
 
dNi tð Þ
(2)
In Equations 1 and 2, the sum is by default over all observations N that fail in the sample. It is also of interest to
estimate instantaneous measures of explained variation, termed local RE, for which the sum is made over the x records
that fail around each successive observed failure times throughout the entire follow‐up. The value of x depends on the
cancer, but the illustrations presented here used a window of 20 failures.
localRE ¼
∑i ∫
tþx=2
t−x=2
1
cGit * ri;null tð Þ− ri;model tð Þ
 
dNi tð Þ
∑i ∫
tþx=2
t−x=2
1
cGit * ri;null tð Þ− ri;perfect tð Þ
 
dNi tð Þ
(3)
2.2 | The excess hazard model
Net survival is the survival that would be observed in our population of cancer patients, had cancer been the only
possible cause of death.16 Net survival can be estimated in the cause‐specific setting or in the relative survival setting.
The main difference between the 2 settings is the knowledge of the cause of death.
In the cause‐specific setting, the exact cause of death is known, and the failure indicator reflects whether the patient
dies from his/her cancer (failure is coded 1), did not die (failure is 0), or died from a cause other than cancer (failure is 0
or 2). It is straightforward to adapt RE to cause‐specific survival models: the only difference is that RE is evaluated at
each cancer death rather than each death (see Figure 1A).
In the relative survival setting, cause of death is not available or not deemed reliable; therefore, population life tables
are used in the modelling of excess mortality to adjust for mortality due to other causes, also termed expected or back-
ground mortality. Population life‐tables reflect the pattern of survival of the general population, from which the cancer
patients are drawn. In population‐based cancer survival, the relative survival setting is the setting of choice for the esti-
mation of net survival through excess hazard modelling.
We aim that RE gives a measure of how much of the cancer survival variation observed between individuals is
explained by a specific excess hazard model: we remove the impact of other causes and isolate the effects of potential
additional variables on cancer mortality.
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2.3 | RE measured from an excess hazard model
(a) Weights
In the same way that consistent estimators of net survival can be obtained in both relative survival and cause‐specific
settings, we want RE calculated in both settings to agree. In the cause‐specific setting, RE is evaluated only at times of
cancer deaths (Figure 1A). By contrast, the relative survival setting uses all failure times regardless the cause of death
(Figure 1B) for which RE needs to be adjusted (Figure 1C).
Therefore, we propose to weight each event time with quantities reflecting the probability that the event is happening
due to the cause of interest at the time considered. We therefore consider
wi ¼ p dNEi tð Þ ¼ 1j dNi tð Þ ¼ 1ð Þ (4)
where NEi tð Þ is the counting process associated with the cause of interest, and Ni(t) is the all‐cause counting process.
We define the weights as the ratio of the excess mortality due to cancer λE, over the sum of the excess and expected
(population, λP) mortality.
17 Both hazards are estimated at the time of death.
wi ¼ w tið Þ ¼ λEi tið ÞλEi tið Þ þ λPi tið Þ
(5)
Take the practical example of the cause‐specific setting: if we were to use weights, differences in ranks would be eval-
uated at times at which patients are censored due to death from other causes, but their weight, hence contribution,
would be 0, because the probability that the event is a cancer death is null. To mirror this in the relative survival setting,
weights would tend to 0 when the probability of cancer death is highly unlikely, and weights would tend to 1 when the
probability of cancer death is highly likely.
We want to show that the total number of cancer events can be estimated by the sum of weights wi. By law of total
probabilities, we have
p dNEi tð Þ ¼ 1ð Þ ¼ p dNEi tð Þ ¼ 1j dNi tð Þ ¼ 1ð Þ * p dNi tð Þ ¼ 1ð Þ þ p dNEi tð Þ ¼ 1j dNi tð Þ ¼ 0ð Þ * p dNi tð Þ ¼ 0ð Þ (6)
FIGURE 1 Calculation of RE in different settings (A) Cancer‐specific setting (B) Relative survival setting (C) Proposed approach:
Weighting in the relative survival setting.◯ time of cancer death; X time of non‐cancer death; | time of censoring; rM: Rank as estimated
from the model‐derived hazard of death; r0: Average rank of the records in the risk set; rP: 1; wi: probability of cancer death [Colour figure can
be viewed at wileyonlinelibrary.com]
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Because p dNEi tð Þ ¼ 1j dNi tð Þ ¼ 0ð Þ ¼ 0, and dN variables are binomial variables, if one sums Equation 6 over
individuals and event times, after changing the order of summation and expectation, one gets:
E ∑ni¼1∑tkdNEi tkð Þ
 
¼ E ∑ni¼1∑tkwi*dNi tkð Þ
 
(7)
Given that dNi(tk) = 1 if and only if ti = tk, Equation 7 can be written as follows:
E ∑ni¼1∑tkdNEi tkð Þ
 
¼ ∑ni¼1wi (8)
The total number of cancer events can thus be estimated by the sum of weights: depending on the quality of the
approximation of the expected mortality hazard by the general population life tables and the excess hazard model to esti-
mate cancer‐specific mortality, the sum of weights will approach the number of cancer deaths.
We define RE for excess hazard models, REw, as follows:
REw ¼
∑i ∫
τ
0
witcGit * ri;null tð Þ− ri;model tð Þ
 
dNi tð Þ
∑i ∫
τ
0
witcGit * ri;null tð Þ− ri;perfect tð Þ
 
dNi tð Þ
(9)
(b) Null models
In order to adapt RE to the relative survival setting, we kept the null model defined in Stare et al13 and presented in
Section 2.1 above; additionally the use of weights reflects the probability that an event is the event of interest.
Nonetheless, alternative null models have been considered, which assume some features of the excess hazard
model a “given”. For instance, we tested a null model that conveyed the life table information. The “null” rank (ri,null)
attributed to each patient at each event time ti was derived from decreasing expected (population) mortality rates
measured at ti.
ri;null ¼ rank λPi tið Þð Þ
It meant that for RE to be large, the effects of variables such as age, present in both the population life tables and the
excess (cancer) hazard model, would need to have a different effect on the expected hazard and on the excess hazard. For
example, age has a strong effect on both the expected mortality and the excess mortality; hence, both ri,null and ri,model,
respectively, are close to 1 for most patients i. Therefore, the individual difference ri,null – ri,model will be slightly positive
only when ri,null > ri,model, ie, when the effect of age on the expected hazard is smaller than the effect of age on excess
mortality. A large βage in the excess hazard model can therefore lead to a small overall RE: a result that is hard to
interpret. Similarly, because some factors can cease to be discriminant for cancer survival years after diagnosis, the indi-
vidual differences ri,null – ri,model become very negative so the local RE and even the overall RE could reach very negative
values.
We also tested a null model that integrated the additive structure of the overall mortality into excess and expected
hazards.
ri;null ¼ rank λPi tið Þ þ λ0 tið Þð Þ
Nonetheless, defining a model which only contained that structure with no further assumption was challenging, and
was confusing the interpretation of RE.
We believe the null model presented and used in Stare et al13 in conjunction with our weighing remains the most
relevant approach for the adaptation of the original RE to excess hazard models. Hence, ri,null represents the mean rank
of all observations in the risk set at time ti, reflecting a complete absence of knowledge on what observation will fail next.
In this way, RE estimated through cause‐specific or relative survival settings using weights will have the same
interpretation.
Several outputs can be defined from the explained variation measure:
(a) Time‐varying REw, REw(t):
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a. it is considered as a function of follow‐up time and reports the values of REw cumulated up to given times
b. REw is the cumulative measure calculated over the entire follow‐up.
This is the main measure together with its variance or confidence interval.
(b) Local REw, an instantaneous measure of REw, measured using events happening between 2 pre‐defined times,
possibly moving through the follow‐up.
This measure is exploratory, designed to investigate further specific explained variation patterns. It is advised to
report smoothed curves of the local instantaneous REw values and time‐varying REw(t).
3 | SIMULATIONS
We performed simulation studies to understand the properties of REw defined in the context of excess hazard models.
The simulations also demonstrate the characteristics of REw such as the information it brings over the usual model out-
puts and how sensitive REw is to model mis‐specification.
3.1 | Simulation strategy
(a) Data
We used information on 5809 breast (women) and 2418 lung (men and women) cancer patients diagnosed in
England in 2000 with a valid stage at diagnosis. The potential maximum follow‐up was 8 years for each patient, to the
31st December 2007, and information on their age, deprivation status, and stage at diagnosis was available. Due to
passive follow‐up, no censoring happens prior to the end of follow‐up. Breast and lung cancers were chosen for their
differing death patterns: 93% of lung cancer patients vs 30% of breast cancer patients die in the 8 years following
diagnosis, and cancer deaths account for nearly 95% and around 60% of all deaths in lung and breast cancer respectively.
(b) Expected survival times
Expected survival times were simulated by extracting expected mortality rates, λP, from sex‐specific, age‐specific,
year‐specific, and deprivation‐specific life tables, defined at each month of age and every calendar month. Moving
forward, at each anniversary day of diagnosis, patient records were merged to these life tables in order to get a
patient‐specific expected mortality rate λP for that exact day. The survival time u, simulated for each patient from an
exponential distribution with mean λP, was compared with 1 month to determine the expected survival time: if u was
always greater than 1, the patient over‐lived every month and was still alive at the end of the 8‐year follow up. The failure
indicator equals to 1 when the subject dies (whatever the cause) or 0 otherwise.
(c) Parameters of the simulations
Fully parametric models were fitted on the log cumulative hazard scale1,11 to model the excess hazard of death using
the STATA command, stpm2. Model‐based information, such as the parameters of the baseline log‐cumulative excess
hazard, and the estimated effect parameters, was used to simulate a thousand survival times (outcome) for each of the
5809 breast and 2418 lung cancer patients. We kept the original values of the patients' sex, age, deprivation, and stage
at diagnosis (observed covariate distribution). The aim of these simulations is that the simulated survival times resemble
realistically observed survival patterns (see annex).
(d) Cancer survival times
We designed 2 simulation scenarios: a simple one, S1 only containing linear proportional effects of age at diagnosis,
and a more complex scenario, S2, with non‐proportional and non‐linear effects of age, and non‐proportional effects of
categorical stage and deprivation (see Box A).
6 MARINGE ET AL.
Survival times for S1 were simulated according to the following function for the log cumulative excess hazard:
ln HS1 t; ageð Þð Þ ¼ ln H0 tð Þð Þ þ βage * age
with ln(H0(t)) = s(ln(t); γ), s being a non‐orthogonalised restricted cubic splines function of ln(t), with up to 3 degrees of
freedom, placed at tertiles of the distribution of times.
Survival times for S2 were simulated according to the following function for the log cumulative excess hazard:
ln HS2 t; age; stage; deprivationð Þð Þ ¼ ln H0 tð Þð Þ þ f age ageð Þ * 1þ ln tð Þð Þ þ ∑
i¼2;3;4
ðβstagei * stagei þ αstagei * ln tð Þ * stageiÞ
þ ∑
i¼2;3;4;5
ðβdepi* depi þ αdepi * ln tð Þ * depiÞ
with ln(H0(t)) = s(ln(t); γ), s being a non‐orthogonalised, restricted cubic splines function of ln(t) with up to 3 degrees of
freedom, placed at tertiles of the distribution of times.
A general algorithm involving numerical integration and root‐finding techniques generated the cancer‐specific sur-
vival times from these complex parametric distributions.18 We used the survsim command implemented in STATA.19
Overall survival time is the minimum between cancer‐specific survival times, as simulated in S1 or S2, expected sur-
vival times derived from population life tables and the maximum follow‐up time (8 years). From each simulated dataset,
we retained the simulated expected, cancer and overall survival times, and the corresponding vital status indicators.
To make sure our simulated excess hazard and survival curves are realistic, we compared them to the original real‐
life hazard and survival curves (Figure 1 in Annex). More details are provided in the tables of bias and coverage (Annex)
for both scenarios S1 and S2.
Because the process that generated the survival times is known, it is straightforward to assess the properties of REw
calculated in several different estimation models. The estimation models M1 and M2 are well‐specified as they include
the same variable structure and form of effects than the simulation scenarios S1 and S2, respectively. The other models
M3 to M10 are mis‐specified because simulation and estimation models differ (see Box A).
We expect 1000 simulated datasets to be sufficient to offer a good overview of the properties of REw. All models were
fitted on each of the 1000 simulated datasets for S1 and S2, and REw, REw(t), and local REw were calculated and their
values retained for the assessment of their properties.
Excess hazard models and cause‐specific hazard models both estimate the same quantity: an estimate of net survival
can be derived from both strategies when cause of death is reliably known. Similar agreement is therefore expected
between the values of RE measured in cause‐specific and REw in relative survival settings.
3.2 | REw—Weighting system
Each individual contribution to REw was weighted by the probability that the event represents a death from cancer. The
sum of these weights over all patients who died is an estimate of the number of cancer deaths in the population. Figure 2
compares the actual number of cancer deaths to the sum of weights, for each of the 2 simulation scenarios S1 and S2 for
breast and lung cancers.
Over the 8 years of follow‐up, there were on average 1070 breast cancer deaths among the breast cancer patients, ie,
18.4% of patients with breast cancer representing around 60% of deaths; and on average 2159 lung cancer deaths in
patients with lung cancer, ie, 90% of patients representing 95% of deaths. Over the 1000 datasets simulated in each of
the 2 scenarios, the sum of the weights, used in the calculation of REw, agreed with the actual number of cancer deaths,
used in the cause‐specific setting (Figure 2).
The agreement between REw values obtained from relative and RE in cause‐specific approaches was nearly perfect,
both in simulation scenarios S1 and S2 for breast and lung cancers, and at 1, 5 and 8 years after diagnosis (Figure 3). The
larger variability observed in the breast cancer plots was expected and shows the greater instability of the excess hazard
models due to the smaller portion that the breast cancer deaths represents among all deaths in that population (60%),
contrasting with the burden of lung cancer deaths in lung cancer patients (95%).
We explored a critical scenario in which cancer mortality is very low compared with all‐cause mortality: we selected
stage I to II breast cancer patients aged 70 to 99 years at diagnosis. In that sample, REw was still behaving properly
despite weights that were slightly over‐estimated. That over‐estimation can have an increasing or decreasing impact
on REw depending on the directions of the effects of factors included in both the life table and the excess hazard model.
MARINGE ET AL. 7
Box A. Simulation and estimation scenarios
S1 Simulation scenario 1, linear proportional effect of age at diagnosis
M1 Linear proportional effect of age
M3 Linear non‐proportional effect of age
M4 Non‐linear proportional effect of age
M5 Non‐linear non‐proportional effect of age
S2 Simulation scenario 2, non‐linear non‐proportional effect of age, non‐proportional effects of
categorical stage and deprivation
M2 Non‐linear non‐proportional effect of age, non‐proportional effects of categorical stage and deprivation
M6 Non‐linear non‐proportional effect of age, non‐proportional effect of categorical deprivation
M7 Non‐linear non‐proportional effect of age, non‐proportional effect of categorical stage
M8 Linear proportional effect of age, categorical stage and deprivation
M9 Non‐linear non‐proportional effect of age, proportional effect of categorical stage, non‐proportional effect
of categorical deprivation
M10 Non‐linear non‐proportional effect of age, non‐proportional effect of categorical stage, proportional effect
of categorical deprivation
FIGURE 2 Sum of weights and actual number of cancer deaths, for each of a 1000 simulated datasets, by cancer and simulation scenario.
S1: Simulation scenario 1, linear proportional effect of age at diagnosis; S2: Simulation scenario 2, non‐linear non‐proportional effect of age,
non‐proportional effects of categorical stage and deprivation [Colour figure can be viewed at wileyonlinelibrary.com]
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It is good practice to report the estimated number of cancer deaths, and their proportion among all deaths, as esti-
mated by the sum of weights, so the interpretation of the outputs is given the required caution. Some degree of instability
in the estimates of effects is indeed expected in excess hazard models where there is a low proportion of cancer deaths
among all deaths.17 REw is based on the excess hazard model and therefore suffers twice (through weighting and rank-
ing of events) in such situations. In practice, we follow the recommendation from Sasieni that excess hazard model is
best used when the proportion of death due to the disease of interest is between 30% and 90%.20
3.3 | REw—Properties
Mis‐specifying the form of the effects of the main prognostic factors hardly affected REw. In simulation scenario S1 (sim-
ple linear proportional effect of age), the over‐parameterisation of age in the modelling, by inclusion of non‐linear and/or
non‐proportional effects of age (models M3‐M5), did not alter REw: median REw, at 0.035 (breast) and 0.095 (lung) with
model M1, increased to 0.037 to 0.043 (breast) and remained unchanged for lung (Figure 4).
The impact of stage, a strong predictor of survival, on REw is obvious when stage was omitted in the modelling (M6)
while it was present in the simulation scenario (S2): median REw decreased from 0.600 (M2) to 0.213 (M6) for breast, and
from 0.421 (M2) to 0.126 (M6) for lung (Figure 4). All other types of model mis‐specification, such as omitting depriva-
tion (M7), or omitting/including non‐linearity or non‐proportionality of age, deprivation or stage (M8‐M10), did not have
any strong impact on REw: for both breast and lung cancers, the largest differences in median REw occurred with under‐
parameterisation of stage, ie, lack of non‐proportionality of the effect (M8, M9), and still showed a difference in median
REw as small as 0.02 or less.
REw is robust to model mis‐specification because the ranking of the individual hazards is unaffected by estimated
changes in the strength of the effects only. M6, in which the effect of stage is ignored, shows greater impact on REw
due to large changes in the ranking of observations.
The local REw was calculated using 20 events around each index event. This choice resulted in windows of varying
lengths: stable at around 25 days all through the follow‐up for breast cancer patients, whereas it started at less than
20 days for the first year of lung cancer follow‐up, and then gradually increased to 450 days beyond 7 years. Indeed, over
75% of deaths occurred in the year following the lung cancer diagnosis, although it takes 5 years to observe 75% of deaths
for breast cancer patients.
There was little variation between the 1000 local REw curves when simulation and estimation models coincided, ie,
M1 in S1 and M2 in S2 (Figure 5). The general patterns of local REw seen in well‐specified models were however pre-
served for mis‐specified estimation models. In the simple scenario S1, local REw remained relatively constant with time
since diagnosis for all models. For the more complex simulation scenario S2, the local REw curves decreased with time
for all models. We further explored that decrease in local REw to understand what effect it reflected. We looked at sim-
ulated data following 2 additional scenarios, S3 and S4: S3 included linear proportional effects of age, and proportional
effects of categorical deprivation and stage at diagnosis, while S4 included non‐linear and non‐proportional effects of age,
FIGURE 3 Comparison of RE obtained in cause‐specific and relative survival settings, by cancer and simulation scenario
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and non‐proportional effects of categorical deprivation. While the local REw curves also decreased in simulation sce-
nario S4, they remained constant in S3 indicating that non‐proportional effects of age and other factors, rather than
the adjustment for stage, triggered a decreasing local REw in S2.
The weighting initially proposed in Stare et al takes good account of random censoring through time. However, in the
event that some cohorts of patients are all censored at a fixed date, such as due to administrative censoring when
performing a complete study design, this weighting was not sufficient to cope for such large amount of censored
information, often tied. We advise to break ties by simply adding or subtracting a small fraction of time to the survival
times that tie. It will then prevent the spurious increasing REw emanating from large proportions of patients censored at
similar times after diagnosis. Without this correction, local and overall REw will also converge to 1 from the time heavy
censoring starts occurring. For users analysing a cohort study design, it is advised to measure the cumulative REw right
before the administrative censoring happens.
4 | APPLICATION: COMPLEX MULTIVARIABLE MODELLING
Given the availability of potential predictors of cancer survival in England, we selected patients diagnosed with colon
cancer in 2011 to 2013 (n = 9300) or non‐small cell lung cancer in 2012 (n = 5958), with follow‐up until the end of
2014. We selected a 25% random sample of patients with valid information on sex, age at diagnosis, deprivation, stage
at diagnosis, major surgical treatment, and comorbidity (Charlson index, CCI) for all patients and additional information
on performance status and route to diagnosis for lung cancer patients only (Table 1).
The initial parametric log‐cumulative excess hazard models, stratified by sex, included age at diagnosis and depriva-
tion, and expected hazards were provided by life tables defined by sex, single year of age, and deprivation. We aimed to
measure the explained variation of the increasingly more complex models to reflect the explained variation of each factor
successively added into the models.
The sum of the weights derived for the calculation of REw quantified the proportion of cancer deaths among all
deaths. Of the 40.6% (42.0%) colon cancer patients dying through the follow‐up, we estimated that 79.0% (83.4%) died
FIGURE 4 REw measured at 5 years, using different well‐specified (M1, M2, plain lines) and mis‐specified (M3‐M10) models, by cancer
and simulation scenario. S1: Simulation scenario 1, linear proportional effect of age at diagnosis; M1: Linear proportional effect of age
(plain line across M3‐M5); M3: Linear non‐proportional effect of age; M4: Non‐linear proportional effect of age; M5: Non‐linear non‐
proportional effect of age; S2: Simulation scenario 2, non‐linear non‐proportional effect of age, non‐proportional effects of categorical stage
and deprivation (plain line across M6‐M10); M2: Non‐linear non‐proportional effect of age, non‐proportional effects of categorical stage and
deprivation; M6: Non‐linear non‐proportional effect of age, non‐proportional effect of categorical deprivation; M7: Non‐linear non‐
proportional effect of age, non‐proportional effect of categorical stage; M8: Linear proportional effect of age, categorical stage and deprivation;
M9: Non‐linear non‐proportional effect of age, proportional effect of categorical stage, non‐proportional effect of categorical deprivation; M10:
Non‐linear non‐proportional effect of age, non‐proportional effect of categorical stage, proportional effect of categorical deprivation
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of cancer in men (women); and of the 86.4% (81.3%) of dead men (women) lung cancer patients, 94.3% (95.0%) died of
their cancer.
Table 2 shows that REw reached 0.22 (95%CI: 0.16–0.28) (REw = 0.26, 95%CI: 0.20–0.31) in men (women) with colon
cancer, and 0.14 (95%CI: 0.11–0.17) (REw = 0.16, 95%CI: 0.12–0.19) in men (women) with lung cancer at 12 months after
diagnosis, for models adjusted for age and deprivation only, ie, the baseline model. Full adjustment for all available
covariables increased REw to 0.69 (95% CI: 0.67–0.70) (REw = 0.67, 95%CI: 0.66–0.69) in men (women) with colon can-
cer and 0.56 (95%CI: 0.54–0.58) (REw = 0.58, 95%CI: 0.56–0.60) in men (women) with lung cancer. Stage accounted for
most of the increase in colon cancer, explaining 61.8% (53.5%) in men (women) of the explained variation of the full
model, and increasing the baseline REw by over 150%. In lung cancer, performance status and stage showed the largest
increase in REw, from the minimum initial model: around 200%, with an absolute change in REw of 0.29 (0.30) and 0.28
(0.29) in men (women) respectively; but in a full model, their respective shares represented 12.4% (10.8%) and 10.5%
(7.4%) in men (women), suggesting correlation between variables such as treatment and stage, or emergency presenta-
tion and stage.
We then measured time‐varying REw at 1 month and every 3 months following diagnosis, up to 3 years (Figures 6A
and 7A). In colon cancer patients, there is a clear distinction between models that do and do not contain stage at diag-
nosis. In models excluding stage, REw(t) was stable from 12 months after a sharp decrease in the first 6 months and
then slight decrease until the 12th month (Figure 6A). The local REw showed evidence that at 2 years after diagnosis,
models that contained the surgical treatment variable, without stage at diagnosis, displayed an increased local REw
(Figure 6B).
In lung cancer models, the time‐varying REw increased from the baseline age and deprivation model with any addi-
tional variable: REw(t) was stable after a slight decrease until 3 months, mostly in women, and in models adjusted for
emergency presentation (from over 0.5 in women to less than 0.4, Figure 7A). Additionally, the curves reflecting pres-
ence of stage and performance status reflect perfectly the large contribution of performance status at the start of the fol-
low‐up, and the constant contribution of stage. The patterns of the local REw curves are suggestive of a late treatment
FIGURE 5 Local REw measured up to 5 years, for different well‐specified (M1, M2) and mis‐specified models (M3‐M5 and M6‐M10): breast
and lung cancers. S1: Simulation scenario 1, linear proportional effect of age at diagnosis; M1: Linear proportional effect of age; M3: Linear
non‐proportional effect of age; M4: Non‐linear proportional effect of age; M5: Non‐linear non‐proportional effect of age; S2: Simulation
scenario 2, non‐linear non‐proportional effect of age, non‐proportional effects of categorical stage and deprivation; M2: Non‐linear non‐
proportional effect of age, non‐proportional effects of categorical stage and deprivation; M6: Non‐linear non‐proportional effect of age, non‐
proportional effect of categorical deprivation; M7: Non‐linear non‐proportional effect of age, non‐proportional effect of categorical stage; M8:
Linear proportional effect of age, categorical stage and deprivation; M9: Non‐linear non‐proportional effect of age, proportional effect of
categorical stage, non‐proportional effect of categorical deprivation; M10: Non‐linear non‐proportional effect of age, non‐proportional effect of
categorical stage, proportional effect of categorical deprivation
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TABLE 1 Number and proportion of patients, by stage at diagnosis and each of the main explanatory factors: Lung cancer patients diag-
nosed in 2012, colon cancer patients diagnosed in 2011 to 2013 in England
Non‐Small Cell Lung Cancer
Men Women
Stage I Stage II Stage III Stage IV Total Stage I Stage II Stage III Stage IV Total
Age at diagnosis
Mean (sd) 72.8 (10) 72.9 (10.2) 72.1 (10.06) 72.3 (10.4) 72.6 (10.7) 72.6 (11) 72.1 (10.5) 72.2 (11.1)
Treatment No. % No. % No. % No. % No. % No. % No. % No. % No. % No. %
No major surgical
treatment
223 44.2 149 52.3 753 89.1 1658 99.0 2783 84.1 214 44.7 123 52.1 528 89.0 1327 98.9 2192 82.7
Major surgical
treatment
281 55.8 136 47.7 92 10.9 16 1.0 525 15.9 265 55.3 113 47.9 65 11.0 15 1.1 458 17.3
Emergency presentation
No 425 84.3 237 83.2 657 77.8 1016 60.7 2335 70.6 367 76.6 186 78.8 452 76.2 767 57.2 1772 66.9
Yes 79 15.7 48 16.8 188 22.2 658 39.3 973 29.4 112 23.4 50 21.2 141 23.8 575 42.8 878 33.1
Performance status
High—0 168 33.3 87 30.5 201 23.8 230 13.7 686 20.7 138 28.8 66 28.0 122 20.6 177 13.2 503 19.0
1 186 36.9 114 40.0 321 38.0 521 31.1 1142 34.5 171 35.7 86 36.4 220 37.1 435 32.4 912 34.4
2 83 16.5 47 16.5 147 17.4 388 23.2 665 20.1 77 16.1 48 20.3 108 18.2 268 20.0 501 18.9
3 51 10.1 27 9.5 121 14.3 370 22.1 569 17.2 63 13.2 29 12.3 115 19.4 306 22.8 513 19.4
4 7 1.4 3 1.1 36 4.3 126 7.5 172 5.2 12 2.5 3 1.3 20 3.4 124 9.2 159 6.0
Low—5 9 1.8 7 2.5 19 2.2 39 2.3 74 2.2 18 3.8 4 1.7 8 1.3 32 2.4 62 2.3
Deprivation quintile
Least deprived 81 16.1 35 12.3 107 12.7 241 14.4 464 14.0 54 11.3 32 13.6 74 12.5 165 12.3 325 12.3
2 84 16.7 51 17.9 139 16.4 269 16.1 543 16.4 85 17.7 39 16.5 93 15.7 194 14.5 411 15.5
3 93 18.5 56 19.6 161 19.1 355 21.2 665 20.1 83 17.3 50 21.2 130 21.9 264 19.7 527 19.9
4 100 19.8 70 24.6 224 26.5 365 21.8 759 22.9 119 24.8 50 21.2 141 23.8 367 27.3 677 25.5
Most deprived 146 29.0 73 25.6 214 25.3 444 26.5 877 26.5 138 28.8 65 27.5 155 26.1 352 26.2 710 26.8
Charlson comorbidity score
None—0 256 50.8 165 57.9 524 62.0 1054 63.0 1999 60.4 251 52.4 136 57.6 373 62.9 917 68.3 1677 63.3
1 113 22.4 52 18.2 141 16.7 295 17.6 601 18.2 127 26.5 55 23.3 107 18.0 218 16.2 507 19.1
2 54 10.7 37 13.0 83 9.8 169 10.1 343 10.4 47 9.8 28 11.9 56 9.4 98 7.3 229 8.6
>2 81 16.1 31 11.0 97 11.3 156 9.4 365 11.0 54 11.2 17 7.2 57 9.6 109 7.9 237 8.9
Total 504 100.0 285 100.0 845 100.0 1674 100.0 3308 100.0 479 100.0 236 100.0 593 100.0 1342 100.0 2650 100.0
Colon cancer
Men Women
Stage I Stage II Stage III Stage IV Total Stage I Stage II Stage III Stage IV Total
Age at diagnosis
Mean (sd) 70.9 (11.2) 72.5 (11.6) 69.8 (12.6) 72.0 (12) 70.5 (13.3) 73.8 (12) 72.1 (12.7) 71.9 (13.7)
Treatment No. % No. % No. % No. % No. % No. % No. % No. % No. % No. %
No major surgical
treatment
31 4.7 41 2.8 59 4.5 393 25.4 524 10.6 27 4.9 49 3.7 68 6.0 404 30.1 548 12.6
Major emergency
surgery
33 5.0 264 18.2 268 20.6 258 16.7 823 16.6 35 6.3 258 19.7 283 24.8 241 17.9 817 18.8
Major elective
surgery
421 64.4 1028 71.0 845 64.9 321 20.8 2615 52.8 377 67.8 914 69.7 680 59.7 256 19.1 2227 51.2
Minor surgery 169 25.8 115 7.9 131 10.1 573 37.1 988 20.0 117 21.0 91 6.9 108 9.5 442 32.9 758 17.4
Deprivation quintile
Least deprived 140 21.4 318 22.0 290 22.3 331 21.4 1079 21.8 131 23.6 304 23.2 291 25.5 262 19.5 988 22.7
2 154 23.5 325 22.4 307 23.6 343 22.2 1129 22.8 118 21.2 290 22.1 247 21.7 293 21.8 948 21.8
3 150 22.9 318 22.0 266 20.4 329 21.3 1063 21.5 121 21.8 270 20.6 215 18.9 280 20.8 886 20.4
4 117 17.9 269 18.6 251 19.3 321 20.8 958 19.4 114 20.5 238 18.1 205 18.0 301 22.4 858 19.7
Most deprived 93 14.2 218 15.1 189 14.5 221 14.3 721 14.6 72 12.9 210 16.0 181 15.9 207 15.4 670 15.4
Charlson comorbidity score
None ‐ 0 477 72.9 1061 73.3 1015 77.9 1146 74.2 3699 74.7 440 79.1 1037 79.0 923 81.0 1076 80.1 3476 79.9
1 78 11.9 194 13.4 122 9.4 179 11.6 573 11.6 65 11.7 142 10.8 106 9.3 139 10.3 452 10.4
2 49 7.5 108 7.5 91 7.0 116 7.5 364 7.4 31 5.6 78 5.9 62 5.4 66 4.9 237 5.4
>2 50 7.7 85 5.8 75 5.8 104 6.8 314 6.3 20 3.7 55 4.3 48 4.3 62 4.6 185 4.3
Total 654 100.0 1448 100.0 1303 100.0 1545 100.0 4950 100.0 556 100.0 1312 100.0 1139 100.0 1343 100.0 4350 100.0
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TABLE 2 Multivariable model: Explained variation (REw) measured at 12 months after diagnosis, for overall models and individual
variables
Changea in REw
Inclusionb Exclusionb
REw at 12 months
(95% CI)
Difference
in REw
Proportion
of Initial
Model (%)
Difference
in REw
Proportion
of Full
Model (%)
Colon cancer
Men
Initial model: Age, deprivation 0.221 (0.160; 0.282)
Age, deprivation, stage 0.671 (0.657; 0.686) 0.450 203.5 0.427 61.8
Age, deprivation, treatmentc 0.251 (0.195; 0.307) 0.030 13.5 0.016 2.4
Age, deprivation, Charlson
Comorbidty index (CCI)
0.232 (0.171; 0.292) 0.010 4.7 0.003 0.4
Full model: Age, deprivation, stage,
treatment, CCI
0.690 (0.676; 0.704)
Women
Initial model: Age, deprivation 0.256 (0.198; 0.314)
Age, deprivation, stage 0.660 (0.644; 0.675) 0.403 157.5 0.359 53.5
Age, deprivation, treatmentc 0.290 (0.241; 0.340) 0.034 13.4 0.010 1.4
Age, deprivation, Charlson
Comorbidity index (CCI)
0.271 (0.214; 0.329) 0.015 6.0 0.002 0.3
Full model: Age, deprivation, stage,
treatment, CCI
0.671 (0.656; 0.686)
Non‐small cell lung cancer
Men
Initial model: Age, deprivation 0.141 (0.112; 0.171)
Age, deprivation, stage 0.422 (0.403; 0.441) 0.280 198.5 0.058 10.5
Age, deprivation, treatmentd 0.257 (0.235; 0.280) 0.116 81.9 0.003 0.6
Age, deprivation, Charlson
Comorbidity index (CCI)
0.141 (0.111; 0.170) −0.001 −0.5 0.000 0.1
Age, deprivation, performance
status (PS)
0.434 (0.409; 0.459) 0.293 207.3 0.069 12.4
Age, deprivation, presentation
(EP vs non‐EP)
0.325 (0.295; 0.354) 0.183 129.8 0.013 2.4
Full model: Age, deprivation, stage,
treatment, CCI, PS, presentation
0.558 (0.539; 0.576)
Women
Initial model: Age, deprivation 0.155 (0.120; 0.191)
Age, deprivation, stage 0.442 (0.421; 0.463) 0.287 185.1 0.043 7.4
Age, deprivation, treatmentd 0.299 (0.274; 0.324) 0.144 92.8 0.006 1.0
Age, deprivation, Charlson
Comorbidity index (CCI)
0.157 (0.121; 0.192) 0.002 1.0 −0.001 −0.2
Age, deprivation, performance
status (PS)
0.455 (0.427; 0.484) 0.300 193.6 0.063 10.8
Age, deprivation, presentation
(EP vs non‐EP)
0.352 (0.318; 0.387) 0.197 127.2 0.020 3.4
Full model: Age, deprivation, stage, treatment,
CCI, PS, presentation
0.584 (0.564;0.604)
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effect: generally decreasing over time for models including emergency presentation or performance status but increasing
for the model including surgical treatment information (Figure 7B).
By definition of the local REw, the shapes of the smoothed curves are only slightly influenced by the number of
events included in the windows around each index event. For both colon and lung cancers, including 10 events on either
side of the index event resulted in windows of times varying between a day and 50 days for lung cancer or between a day
and over 75 days for colon cancer in the 3 years of follow‐up. The degree of smoothing will also likely impact the shape of
the local REw curves. Furthermore, the cumulative nature of the overall and time‐varying REw means that they are
likely impacted by the high proportions of death happening at the beginning of the follow up: 50% of all deaths occurred
by the 3rd and 9th months of follow‐up in lung and colon cancer, respectively, explaining why REw(t) was mostly flat
beyond these times.
5 | DISCUSSION
We presented here an adaptation of the RE measure for event history data to excess hazard modelling. We offer a new
tool to quantify the variation in disease‐specific outcome explained by the available predictive factors. In this context,
REw can be measured at given time points following diagnosis and plotted as a function of time. Additional exploratory
insight is provided by a “local REw”, calculated using a window of events around each event time. That function of time
can be very unstable, and the smoothed curve is useful to look at the general trend in the variation in RE by the model.
Although dependent on death patterns, these time‐varying versions of REw help understand better when specific factors
have strongest impact on survival.
The differences between local REw and REw(t) curves can be seen similarly to the differences between hazard and
cumulative hazard curves. The cumulative hazard curve is a cumulative measure, whereby hardly affected by local
effects seen in the instantaneous hazard curve. REw(t) is the cumulative REw, heavily impacted by the first few months
following the diagnosis, where most cancer‐related deaths occur. If one is interested in changes in explained variation
due to, say late treatment effects or changes in the composition of the cohort of patients (younger ages, fewer late stage
patients, fitter patients…), the local REw will provide such information. Furthermore, in the context of dynamic data and
dynamic models, local REw will be providing the necessary time‐varying measure of explained variation.
Furthermore, local REw and REw(t) are informative for comparison between studies, or when varying follow‐up
times are available, because the overall measure REw will vary with the available follow‐up.21
Further research in the number of events to include in the calculation of the local REw show very little variation in
the smoothed functions. Only the heights of the spikes seen in the un‐smoothed local REw curves are affected, and hence
the tail of the smoothed curve, where the number of events is more scarce. We advise researchers to use 20 events, as a
default size, and depending on the cancer lethality, check for the impact of using much smaller (say 4–10 events) or
much larger (30–40 events) number of events. The local REw curve will, to some extent, depend on the number of events
as well as the amount of smoothing applied.
The weighting system proposed here for the relative survival setting keeps the simplicity and the intuition of the orig-
inal RE used in the overall and cause‐specific settings. It also retains the original RE measure's properties such as model‐
free interpretation. Furthermore, the weighted measure REw in the relative survival setting is equivalent to RE in the
cause‐specific setting.
Multidimensional models defined on the log or log‐cumulative hazard scales can now be routinely used to estimate
excess hazard from cancer.3,11 These models often include complex non‐linear and non‐proportional effects of a variety
of factors that may impact levels of survival. Therefore, the regression coefficients are not straightforward to interpret,
Modelled effects: Age: non‐linear and non‐proportional, Deprivation: categorical, non‐proportional, Stage: categorical, non‐proportional, Treatment: categorical,
non‐proportional, CCI: linear, non‐proportional, Performance status: categorical, Presentation binary: emergency presentation (EP) versus non‐emergency.
aChange is measured as the arithmetic difference between the initial (inclusion) or full (exclusion) model REw and the model that includes the specific variable.
That difference is expressed as a proportion of the initial (inclusion) or full (exclusion) model.
bInclusion: change in REw with the addition of the index variable to a model including age and deprivation. Exclusion: change in Rew with the removal of the
index variable from the full model.
cThe variable “treatment” represents major surgical resection.
dThe variable “treatment” represents both treatment and the route to diagnosis: 1—no treatment, 2—emergency major surgery, 3—elective major surgery, 4—
minor surgery.
Notes to Table 2
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and strong predictors are often hard to pin down. We propose to look at differences in REw between models to quantify
the proportion of variation explained by a given factor. Our illustration shows that for lung cancer patients, performance
status explained the largest amount of variation in survival between patients, particularly in the early months following
diagnosis. Performance status, although well‐known and discussed in Multi‐Disciplinary Team meetings, is rarely
accounted for in epidemiology, mainly because of its unavailability in the routine cancer registration datasets. Such high
explanatory power for that variable could trigger its availability at least in specialised cancer registry datasets.
Low proportions of explained variation for single covariable in the full model, whereas each additional variable adds,
individually, a lot to the explained variation of the baseline model, indicate high correlation between factors. It could
reflect a high adherence to guidelines such that whole groups of patients got administered the same treatment, or were
diagnosed via a given ideal route.
Despite the measure being dependent on the excess hazard model through the weighting and through the ranking of
observations, REw proved a great stability to model specification. REw was largely insensitive to over‐parameterisation
or under‐parameterisation of the variables used in the simulation model. Non‐linear or non‐proportional effects,
although they may reflect better the reality of the estimated disease‐specific survival, will not impact dramatically the
order at which patients will experience the event of interest.
FIGURE 6 Multivariable models: (A) explained variation measured at 1 month and every 3 months after diagnosis, (B) smoothed local RE
up to 3 years after diagnosis, for models adjusted for the effects of age and deprivation, and stage, and treatment. Colon cancer patients
diagnosed in 2011 to 2013, selected for their valid stage at diagnosis: 4950 men and 4350 women the curve for comorbidity is not presented
here as it is undistinguishable from the age and deprivation model
Notes: (1) RE(t) and local RE can have values between −1 and +1 (2) Cumulative RE, RE(t) is calculated at month 1, 3, 6…36 after diagnosis
(3) Local RE is calculated using information from 10 events on either side of the index event. The smoothed (lowess with mean smoother)
curve is presented here
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REw, like RE, is not exact. Small sample sizes or low number of deaths due to the disease of interest will increase
variability around the estimated REw. Therefore, we advise users to report the variance or confidence interval obtained
around the estimated REw. Similar to RE, REw estimates may be biased for a factor with a small effect.13 However, the
bias will become negligible as the sample size increases.
Further developments will include testing the REw on dynamic models that include time‐varying variables,22 and
in hierarchical models.2 The variation explained by these models may be greater, because they allow the effect of
time‐varying variables to be modelled and, hence, measures of prognostic factors that are updated over time since the
cancer diagnosis.
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FIGURE 7 Multivariable models: (A) explained variation measured at 1 month and every 3 months after diagnosis, (B) smoothed local RE up
to 3 years after diagnosis, for models adjusted for the effects of age and deprivation, and stage, treatment, performance status, and emergency
presentation. Non‐small cell lung cancer patients diagnosed in 2012, selected for their valid stage and performance status at diagnosis: 3308 men
and 2650 women. The curve for comorbidity is not presented here as it is undistinguishable from the age and deprivation model
Notes: (1) RE(t) and local RE can have values between −1 and +1 (2) Cumulative RE, RE(t) is calculated at month 1, 3, 6…36 after diagnosis
(3) Local RE is calculated using information from 10 events on either side of the index event. The smoothed (lowess with mean smoother)
curve is presented here
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